Mylan launches Sovaldi tablets in India

Pharma giant Mylan NV today said its subsidiary Mylan Pharmaceuticals has launched Gilead Sciences' Sovaldi (sofosbuvir 400mg tablets) in the country.
Sovaldi is indicated for the treatment of chronic hepatitis-C infection as a component of a combination antiviral treatment.
It is estimated that around 12 million people are chronically infected with hepatitis-C in India, Mylan said in a release.
In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India.
Mylan president Rajiv Malik said they have a history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality and affordable HIV/AIDS antiretrovirals.

"We are proud to continue our work together with the launch of Sovaldi as it supports our joint commitment to meeting the unmet medical needs of patients in India," Malik said.
Gregg Alton, Executive Vice-President, Corporate and Medical Affairs, Gilead Sciences said it makes an important milestone in the company's ongoing effort to make its hepatitis-C medicines accessible to as many patients, in as many places, as quickly as possible.
Sovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.